GlassScriptPhysician profile
Nilem Patel
NPI 1689837171
$4,842.74
in general payments reported to CMS, 2019-2025
26 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $2,160 · 2021: $57.21 · 2022: $195 · 2023: $506 · 2024: $472 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357 · Travel and Lodging: $4.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.59 |
| Travel and Lodging | $4.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $2,082.24 | 2019-2020 | |
| Medtronic, INC. | $507.63 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Accurian |
| Lilly USA, LLC | $253.33 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Ucb, INC. | $237.14 | 2019-2020 | |
| Dexcom, INC. | $228.36 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $226.69 | 2019-2024 | Freestyle Libre 3 |
| Amgen INC. | $191.69 | 2019-2025 | Otezla, Enbrel, Tepezza |
| Novo Nordisk INC | $163.74 | 2019-2023 | Rybelsus, Ozempic |
| Insulet Corporation | $119.33 | 2019-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $101.83 | 2023-2024 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $96.28 | 2025 | Yorvipath |
| Abbvie INC. | $76.88 | 2023-2024 | |
| Glaxosmithkline, LLC. | $74.15 | 2019-2025 | Benlysta |
| Mallinckrodt Enterprises LLC | $72.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $64.19 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $63.36 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $50.42 | 2019 | |
| Mannkind Corporation | $48.14 | 2019-2020 | |
| Gilead Sciences, INC. | $27.49 | 2024 | |
| Sandoz INC. | $25.27 | 2024 | Hyrimoz |
| Shire North American Group INC | $24.67 | 2019 | |
| Valeritas, INC. | $24.67 | 2019 | |
| Radius Health, INC. | $24.30 | 2019 | |
| Averitas Pharma INC. | $20.55 | 2024 | Qutenza |
| Janssen Biotech, INC. | $19.19 | 2022 | |
| Sequel Med Tech, LLC | $18.64 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilem Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.